L&T-TECHNOLOGY-SERVICES
1.12.2017 13:02:10 CET | Business Wire | Press release
L&T Technology Services Limited consolidated its position as the country’s leading pure-play engineering services company after being rated as a leader across 10 major industries in the Zinnov Zones 2017 Product Engineering Services report. The Zinnov report cited LTTS’ well diversified digital solutions portfolio, focus on critical futuristic technologies and transformational deal wins with customers as major factors driving the momentum.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171201005212/en/
Zinnov rated L&T Technology Services as a leader across verticals such as Automotive, Aerospace, Telecom, Semiconductors, Consumer Electronics, Energy & Utilities, Industrial Automation, Transport, Construction & Heavy Machinery and Medical Devices.
The Zinnov Zones 2017 Product Engineering Services ratings also highlighted a significant leap in LTTS’ Embedded Technology capabilities underpinned by an exhaustive portfolio of proprietary solutions that has made LTTS an ideal design partner in the embedded systems space.
Zinnov rated LTTS as the leader in its Industrial Automation and Construction & Heavy Machinery practices based on its capabilities. Zinnov rated LTTS’ capabilities based on its practice maturity, domain expertise, infrastructure capabilities, strategic innovation, breadth of services across the PDLC and leverage of ecosystem connects. This is the seventh consecutive and fifth consecutive year in which L&T Technology Services has been distinguished as a leading player by Zinnov in Industrial Automation and construction & heavy machinery respectively.
“L&T Technology Services continues to dominate the Engineering services space due to its new age proprietary solutions, 38 R&D Labs spread across its delivery centers, focus on futuristic technologies such as perceptual engineering and neural systems and a client centric ethos that has seen some large deal wins driving the company’s topline,” said Mr Sidhant Rastogi, Partner & Practice Head, Zinnov.
“We are also encouraged by the traction in LTTS’ digital business led by the company’s Intellectual Property and platform solutions. A diversified digital services portfolio & strategic focus on top customers augurs well for the company’s prospects as a leader in ER&D,” Mr Rastogi added.
“LTTS’ ability to win Large & Strategic Transformation deals using the technology pillars of digital engineering, perceptual engineering, pervasive technologies and smart manufacturing have enabled LTTS to be a leader in Zinnov’s annual ratings. This reaffirms the confidence our customers have placed in us and we will continue to invest in Embedded, IIoT and Hi-Tech capabilities that will consolidate our position as the global leader in pure play engineering services,” said Mr Ashish Khushu, Chief Technology Officer, L&T Technology Services Limited.
"Zinnov Zones 2017 – Product Engineering Services” rates 40+ service providers on their product engineering prowess. Service providers are assessed based on multiple dimensions such as spread and maturity of delivery and services capabilities, scalability, growth rate, financials, innovation & IP, ecosystem linkages and feedback from enterprise buyers. For additional details, please visit:
http://zinnovzones.com/Product-Engineering-Services
About L&T Technology Services Limited:
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 52 Fortune 500 companies and 48 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have around 11,000 employees spread across 15 global delivery centers, 28 global sales offices and 38 innovation labs in India as of September 30, 2017. For additional information about L&T Technology Services log on to www.LntTechservices.com .
About Zinnov:
Zinnov was founded in 2002, with presence in Bangalore, Gurgaon, Silicon Valley, and Houston. Since its inception, Zinnov has built in-depth expertise in Product Engineering and Digital Transformation. With a strong foundation in Research and Strategy Consulting they enable their clients to accelerate growth and create efficiencies through innovation, productivity, technology, networked economies and cost savings. They work with clients in the Software, Automotive, Telecom & Networking, Consumer Electronics, Storage, Healthcare, Financial Services & Retail, Semiconductor verticals in US, Europe, Japan & India. For any further media queries, please contact Nitika Goel at media@zinnov.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20171201005212/en/
Contact:
L&T Technology Services Limited
Aniruddha Basu
+91-80-67675173
Aniruddha.Basu@LntTechservices.com
or
Zinnov
Nitika
Goel
media@zinnov.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom